Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

Business Context and Reporting Period

This Form 8-K Current Report was filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp as indicated in metadata) on January 14, 2022, covering events occurring between January 14 and January 21, 2022. The filing details significant executive leadership changes, including the resignation of the CEO and the appointment of new officers.

Key Financial Metrics

This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and separation agreements.

  • CEO Separation Cash Payment: $187,250 (one-time lump sum).
  • CEO Separation Salary Continuation: Nine months of annual base salary.
  • CEO Equity Acceleration: 15,241 RSUs, 15,241 performance units, and 12,500 RSUs.
  • New CEO Base Salary: $453,000 per year (payable via equity award).
  • New CEO Bonus Target: Up to 75% of base salary (payable in stock).
  • New President/COO Base Salary: $295,000 per year.
  • New President/COO Bonus Target: Up to 50% of base salary.

Material Changes

The primary material change is the complete restructuring of the company's top executive leadership:

  • Departure of CEO: Jack Peurach resigned as President, CEO, and Director effective January 21, 2022. The resignation is not due to any disagreement with the Company.
  • Appointment of CEO: Steven Sherman, previously Chairman of the Board, was appointed CEO effective January 22, 2022.
  • Appointment of President/COO: Scott Davis was appointed President and Chief Operating Officer effective January 22, 2022.
  • Board Committee Restructuring: The Strategy Committee was disbanded. New committee assignments were made for the Audit, Compensation, and Nominating and Governance committees.

Guidance, Outlook, and Risks

The filing does not provide financial guidance, revenue outlook, or management commentary on future business performance. The document notes that the resignation of the former CEO was not related to any disagreement regarding operations, policies, or practices. The primary risk highlighted is the transition of leadership and the associated compensation costs outlined in the separation and employment agreements.

Investor Verification Checklist

  • Verify the total cost of the CEO separation package, including the value of accelerated equity vesting.
  • Confirm the vesting schedule and performance metrics for the new CEO's equity award and bonus.
  • Review the full text of the Executive Separation Agreement (Exhibit 10.1) and Employment Agreements (Exhibits 10.2 and 10.3) for additional covenants or restrictions.
  • Assess the impact of the new leadership team's background on the company's strategic direction.
  • Monitor subsequent filings for any changes to the Board composition or committee structures.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.